A compressed candy containing a food-grade ingredient with hypoglycemic effect and its preparation method

By leveraging the multi-level synergistic effects of ingredients that are both medicinal and edible and employing a low-temperature preparation process, the problems of easy attenuation of active ingredients and uneven quality in existing compressed candies have been solved, achieving multi-target hypoglycemic effects and product stability.

CN123100726APending Publication Date: 2026-11-17YANTAI YUANLIDE MARINE ORGANISM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611288864.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing blood sugar-lowering tablets lack a multi-target, multi-level systemic synergistic mechanism in their formulation design, and the active ingredients in the preparation process are easily affected by high temperatures, leading to functional degradation and inconsistent product quality.

Method used

By utilizing the multi-level synergistic effects of medicinal and edible ingredients such as inulin, mulberry leaf, white kidney bean extract, and L-arabinose, combined with low-temperature pulverization and drying processes, a compressed candy with multi-target hypoglycemic effects was prepared.

Benefits of technology

It achieves full-chain blockade of carbohydrate digestion, regulation of incretin and gut microbiota, ensuring the preservation of the bioactivity of active ingredients and the stability of product quality, and providing dual regulation of multiple blood sugar lowering pathways.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100726A_ABST
    Figure CN123100726A_ABST
Patent Text Reader

Abstract

This invention relates to a compressed candy containing medicinal and edible ingredients with hypoglycemic effects and its preparation method, belonging to the field of functional food technology. The compressed candy is composed of inulin, mulberry leaf, white kidney bean extract, L-arabinose, konjac flour, tangerine peel, poria cocos, kudzu root, bitter melon, yam, sea cucumber peptide, resistant starch, and excipients. This invention utilizes the synergistic inhibition of carbohydrate digestive enzyme activity by white kidney bean extract, L-arabinose, and mulberry leaf, combined with sea cucumber peptide to regulate incretin levels, and dietary fiber to delay glucose release, forming a multi-target synergistic hypoglycemic mechanism. The preparation process employs a low-temperature granulation and drying process, effectively preserving heat-sensitive active ingredients and overcoming the difficulty of tableting multi-source natural materials. All raw materials in this invention are medicinal and edible or food-grade excipients, ensuring high safety and making it suitable as a daily supplementary functional food for lowering blood sugar.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of functional food technology, specifically to a compressed candy containing medicinal and edible ingredients with hypoglycemic effects and its preparation method. Background Technology

[0002] Compressed candies, as a food form that combines portability and good taste, have experienced rapid development in the functional food field in recent years. Currently, there are several compressed candy products and related patent applications with auxiliary hypoglycemic effects, whose formulations mostly revolve around a single or a few known hypoglycemic ingredients. For example, existing technologies disclose hypoglycemic vegetable and fruit compressed candies using bitter melon polypeptides, white kidney bean extract, mulberry leaf extract, and L-arabinose as raw materials; other technologies use Cyclocarya paliurus extract, fermented Cordyceps militaris powder, wolfberry extract, and Poria cocos extract as the main active ingredients to prepare compressed candies; in addition, there are compressed candies made from selenium-enriched Polygonatum sibiricum and selenium-enriched Pueraria lobata, which are both medicinal and edible ingredients. While these solutions achieve the function of auxiliary hypoglycemic effects to a certain extent, their hypoglycemic pathways are relatively simple, mainly relying on the single-point inhibition of carbohydrate digestive enzymes or the single-point promotion of insulin secretion by individual components, lacking a multi-target, multi-level systemic synergistic mechanism. Meanwhile, existing products rarely take into account the synergistic integration of multiple hypoglycemic pathways, such as the inhibition of the entire chain of carbohydrate digestive enzymes, regulation of incretin, intestinal slow release, and regulation of gut microbiota, in their formulation design. The comprehensiveness and stability of the hypoglycemic effect still need to be improved.

[0003] Furthermore, existing hypoglycemic aid tablets have several shortcomings in their manufacturing processes. The active ingredients, such as α-amylase inhibitors in white kidney bean extract, 1-deoxynojirimycin (DNJ) in mulberry leaves, and various plant polypeptides, are generally heat-sensitive. Traditional tablet manufacturing often employs high-temperature drying conditions, which can easily lead to activity degradation of these functional components during the process. Simultaneously, the significant differences in the physicochemical properties of multi-source natural materials can cause technical problems during direct tableting, including poor flowability, insufficient compressibility, large variations in tablet weight, and difficulty in balancing hardness and disintegration. Moreover, some existing products add large amounts of sucrose or sweeteners to improve taste and formability, which actually increases sugar intake, contradicting the initial goal of blood sugar control. Therefore, how to scientifically combine multiple medicinal and edible hypoglycemic components without relying on large amounts of sweeteners, and maximize the preservation of the biological efficacy of each active ingredient through a gentle manufacturing process, while ensuring good tablet formability, uniformity, and stability, is a pressing technical problem to be solved in the current field of hypoglycemic aid tablets. Summary of the Invention

[0004] In order to solve the problems of the prior art, the present invention provides a compressed candy with a medicinal and edible homologous ingredient that has a hypoglycemic effect and a preparation method thereof.

[0005] To solve the above-mentioned technical problems, the present invention is achieved through the following technical solution: Firstly, a compressed candy containing a medicinal and edible homologous ingredient with hypoglycemic effect and a preparation method thereof, prepared from the following raw materials in parts by weight: Inulin 5-20 parts, mulberry leaf 3-15 parts, white kidney bean extract 10-30 parts, L-arabinose 5-20 parts, konjac powder 3-15 parts, dried tangerine peel 2-10 parts, poria cocos 3-12 parts, kudzu root 3-12 parts, bitter melon 3-12 parts, yam 3-12 parts, sea cucumber peptide 1-10 parts, resistant starch 5-20 parts, microcrystalline cellulose 5-20 parts, dicalcium phosphate 0.5-5 parts, magnesium stearate 0.5-3 parts.

[0006] It is understood that the above-mentioned food-medicine homology raw material composition is not only applicable to the preparation of compressed candies, but those skilled in the art can also further prepare the composition into oral preparations such as oral liquids, powders, granules, or capsules without changing the composition of the core active ingredients, according to conventional pharmaceutical techniques. The oral liquid can be prepared by dissolving or suspending water-soluble raw materials in a suitable solvent system (such as purified water or an aqueous medium containing suspending agents and preservatives); the powder can be prepared by directly mixing and dispensing the fine powders of each raw material, or by further pulverizing, sieving, and then uniformly dispensing. All of the above dosage forms are direct or indirect extensions of the technical solution of this invention and fall within the protection scope of this invention.

[0007] In one specific embodiment of the first aspect, it is prepared from the following parts by weight of raw materials: Inulin 8-15 parts, mulberry leaf 5-10 parts, white kidney bean extract 15-25 parts, L-arabinose 8-15 parts, konjac powder 5-10 parts, dried tangerine peel 3-8 parts, poria cocos 5-10 parts, kudzu root 5-10 parts, bitter melon 5-10 parts, yam 5-10 parts, sea cucumber peptide 3-8 parts, resistant starch 8-15 parts, microcrystalline cellulose 8-15 parts, dicalcium phosphate 1-3 parts, magnesium stearate 1-2 parts.

[0008] In one specific embodiment of the first aspect, the white kidney bean extract contains an α-amylase inhibitor, the L-arabinose selectively inhibits the activity of sucrase in the small intestinal mucosa, and the mulberry leaf contains 1-deoxynojirimycin; the three synergistically inhibit the process of carbohydrate hydrolysis into monosaccharides, blocking or delaying the generation and absorption of glucose.

[0009] In one specific embodiment of the first aspect, the sea cucumber peptide has the effect of inhibiting dipeptidyl peptidase-IV activity, and the resistant starch is a complex carbohydrate that is not enzymatically broken down by the small intestine; the two work synergistically to delay glucose release and increase insulin levels in the body.

[0010] In one specific embodiment of the first aspect, the microcrystalline cellulose and dicalcium phosphate are used as fillers, and the magnesium stearate is used as a lubricant. The three are used together to improve tableting properties and tablet demolding performance.

[0011] Secondly, a method for preparing a compressed candy containing a food-grade ingredient with hypoglycemic effect includes the following steps: (1) Raw material pretreatment: Mulberry leaves, dried tangerine peel, Poria cocos, kudzu root, bitter melon and yam are pulverized and passed through a 60-120 mesh sieve to obtain fine powder of each raw material; Inulin, white kidney bean extract, L-arabinose, konjac powder, sea cucumber peptide, resistant starch, microcrystalline cellulose, dicalcium phosphate and magnesium stearate are passed through a 60-120 mesh sieve for later use; (2) Mixing and granulation: Weigh all the raw materials except magnesium stearate after step (1) according to the weight parts, put them in a mixer and mix them evenly to obtain a mixture; add an ethanol aqueous solution as a wetting agent to the mixture, stir to make a soft material, and granulate it through a 10-30 mesh sieve. (3) Drying: Place the wet granules obtained in step (2) in a drying device and dry them until the moisture content of the granules is 3% to 8% to obtain dry granules; (4) Granulation and mixing: The dry granules obtained in step (3) are granulated by passing them through a 10-30 mesh sieve, and then magnesium stearate is added and mixed evenly to obtain granules for tableting. (5) Tableting: Place the tableting granules obtained in step (4) into a tablet press and compress them into tablets to obtain tablets containing food and medicine homologous ingredients with hypoglycemic effect.

[0012] In one specific embodiment of the second aspect, the volume concentration of the ethanol aqueous solution in step (2) is 50% to 95%, and the mixing time is 10 to 60 minutes.

[0013] In one specific embodiment of the second aspect, the drying equipment in step (3) is an oven or a fluidized bed drying equipment, the drying temperature is 40-60℃, and the moisture content of the dried particles is 4%-6%.

[0014] In one specific embodiment of the second aspect, the tableting pressure in step (5) is 5 to 30 kN, and the hardness of the resulting tablet is 30 to 150 N.

[0015] Thirdly, the application of a compressed candy containing a food-grade ingredient with hypoglycemic effect in the preparation of auxiliary hypoglycemic foods or health foods.

[0016] The beneficial effects of this invention are as follows: 1. This invention uses medicinal and edible ingredients as its core, achieving auxiliary hypoglycemic effects through multi-level and multi-target synergistic effects. In the ingredient system, the α-amylase inhibitor contained in white kidney bean extract, L-arabinose, and 1-deoxynojirimycin contained in mulberry leaves work synergistically to act on α-amylase, sucrase, and α-glucosidase, respectively, forming a whole-chain blocking effect on each hydrolysis step in the carbohydrate digestion chain from starch to disaccharides to monosaccharides, reducing the generation of absorbable sugars from the source; sea cucumber peptides reduce the degradation of glucagon-like peptide-1 by inhibiting dipeptidyl peptidase-IV activity, promoting endogenous insulin secretion in a glucose concentration-dependent manner; resistant starch and konjac flour utilize their anti-enzymatic properties and swelling properties to delay the glucose release rate; inulin, as a prebiotic, improves the intestinal flora structure and thus regulates host glucose metabolism; traditional medicinal and edible components such as kudzu root, bitter melon, and yam synergistically enhance the overall hypoglycemic effect through multiple pathways such as improving insulin resistance and promoting glucose utilization. The above-mentioned multiple mechanisms complement and synergistically overcome the limitations of a single mechanism for lowering blood sugar, and achieve dual regulation of postprandial blood glucose fluctuations and basal blood glucose levels; 2. The preparation method of this invention addresses the thermosensitivity and physicochemical differences of the aforementioned multi-source active ingredients. Through a combination of low-temperature pulverization and low-temperature drying, it effectively avoids the activity attenuation of thermosensitive functional components such as α-amylase inhibitors in white kidney bean extract, 1-deoxynojirimycin in mulberry leaves, and active peptides in sea cucumber peptides during the manufacturing process, thus maximizing the preservation of the bioactivity of each raw material. Simultaneously, through precise matching of wetting agent concentration and dosage, strict control of particle moisture, and optimization of lubricant addition timing, the granules are endowed with good flowability and compressibility. This effectively solves common technical problems such as insufficient hardness, slow disintegration, and large differences in tablet weight when directly compressing multi-source natural materials, ensuring the uniformity and stability of the final product's quality. Based on the above, all raw materials in this invention belong to the category of medicinal and edible homologous materials or food-grade excipients, exhibiting high safety for long-term use. They can be widely applied in the fields of daily auxiliary hypoglycemic foods and health foods, possessing significant social benefits and industrialization promotion value. 3. The active components (white kidney bean extract, L-arabinose, mulberry leaf, sea cucumber peptide, etc.) in the formulation of this invention have good water solubility or dispersibility. In addition to compressed candies, this composition can be further prepared into oral dosage forms such as oral liquids, powders, granules or capsules according to conventional pharmaceutical techniques. The dosage form conversion is simple and does not require changes to the composition of the core active ingredients, providing a technical basis for the serial development of products. Attached Figure Description

[0017] Figure 1 This is a schematic diagram of the technical route framework for the compressed candy containing medicinal and edible ingredients with hypoglycemic effects according to the present invention. Detailed Implementation

[0018] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0019] like Figure 1 This invention relates to a compressed candy containing a food-grade ingredient that has a hypoglycemic effect and its preparation method.

[0020] I. Overview of Technical Solution This invention provides a compressed candy containing medicinal and edible ingredients with hypoglycemic effects and its preparation method. The compressed candy uses medicinal and edible herbs and functional food ingredients as its core components, achieving its auxiliary hypoglycemic effect through multi-level and multi-target synergistic effects. Its core hypoglycemic mechanism includes: The first level involves carbohydrate enzyme inhibition: α-amylase inhibitors in white kidney bean extract inhibit the activity of salivary amylase and pancreatic amylase, blocking the breakdown of starch into maltose and glucose; L-arabinose selectively inhibits the activity of sucrase in the small intestinal mucosa, inhibiting the breakdown of sucrose into glucose and fructose; 1-deoxynojirimycin (DNJ) in mulberry leaves inhibits α-glucosidase activity, slowing down the hydrolysis of disaccharides into monosaccharides. These three inhibitors work synergistically at different stages of the carbohydrate digestive chain, forming a complete chain blockade of "starch, disaccharides, and monosaccharides."

[0021] The second level, incretin regulation: Sea cucumber peptides promote insulin secretion in a glucose concentration-dependent manner by inhibiting dipeptidyl peptidase-IV (DPP-IV) activity and reducing the degradation of glucagon-like peptide-1 (GLP-1).

[0022] The third level involves the slow release of dietary fiber and intestinal regulation: resistant starch is not broken down by small intestinal enzymes, thus delaying glucose release and regulating the intestinal flora; glucomannan in konjac flour has excellent swelling properties, which slows down carbohydrate digestion and glucose absorption; inulin, as a prebiotic, can reshape the intestinal flora and improve glucose metabolism.

[0023] The fourth level is traditional Chinese medicine conditioning: ingredients such as kudzu root, bitter melon, yam, tangerine peel, and poria cocos, which are both food and medicine, play an auxiliary role in lowering blood sugar by improving insulin resistance, promoting insulin secretion, and regulating glucose and lipid metabolism.

[0024] The synergistic effect of these various levels forms a complete hypoglycemic pathway of "inhibiting absorption - promoting secretion - delaying release - overall regulation".

[0025] Furthermore, all active components in the formulation of this invention (white kidney bean extract, L-arabinose, mulberry leaf, sea cucumber peptide, etc.) are water-soluble or well-dispersible natural products, possessing the basic physicochemical conditions for preparation into oral liquid or powder dosage forms. Oral liquid dosage forms have the advantages of rapid absorption and convenient administration, making them particularly suitable for people with swallowing difficulties; powder dosage forms retain minimal processing steps, offering the best protection for heat-sensitive active ingredients, and can serve as an effective supplementary form to the compressed candy dosage form of this invention. The preparation of the above dosage forms can be achieved using conventional techniques in the field, and all are reasonable modifications to the technical solutions of this invention.

[0026] II. Raw Material Sources and Quality Control The quality requirements for each raw material used in this invention are as follows: (1) Inulin: Extracted from the tubers of Jerusalem artichoke or chicory, plants of the Asteraceae family, with a purity of ≥90%, an average degree of polymerization of ≥10, and a moisture content of ≤5%.

[0027] (2) Mulberry leaves: dried leaves of mulberry (Morus alba), a plant of the Moraceae family, crushed and passed through an 80-mesh sieve, containing ≥0.5% 1-deoxynojirimycin (DNJ).

[0028] (3) White kidney bean extract: White kidney beans are extracted with water, precipitated with alcohol and dried, and the α-amylase inhibitor activity is ≥3000U / g.

[0029] (4) L-arabinose: It is produced by biological fermentation or chemical synthesis using corn cobs or bagasse as raw materials, with a purity of ≥99%.

[0030] (5) Konjac flour: Konjac flour with glucomannan content ≥80% and particle size ≤200 mesh.

[0031] (6) Dried tangerine peel: the dried, mature peel of tangerine and its cultivated varieties, which is crushed and passed through an 80-mesh sieve.

[0032] (7) Poria: The dried sclerotium of the fungus Poria cocos of the Polyporaceae family, crushed and passed through an 80-mesh sieve.

[0033] (8) Kudzu root: The dried root of the legume Pueraria lobata, after being crushed and passed through an 80-mesh sieve, contains ≥2.0% puerarin.

[0034] (9) Bitter melon: The dried fruit of bitter melon, a plant of the Cucurbitaceae family, is crushed and passed through an 80-mesh sieve.

[0035] (10) Yam: The dried rhizome of Dioscorea opposita, a plant of the Dioscoreaceae family, which is crushed and passed through an 80-mesh sieve.

[0036] (11) Sea cucumber peptide: Small molecule peptides obtained by enzymatic hydrolysis, separation and drying of sea cucumber as raw material, with molecular weight ≤3000Da, peptide content ≥80%, and DPP-IV inhibition rate ≥60% (at a concentration of 2mg / mL).

[0037] (12) Resistant starch: RS2 or RS3 type high resistant starch, with a resistant starch content ≥60%.

[0038] (13) Microcrystalline cellulose: pharmaceutical grade, particle size ≤100 mesh.

[0039] (14) Dicalcium phosphate: food grade or pharmaceutical grade, CaHPO4 content ≥98%.

[0040] (15) Magnesium stearate: food grade or pharmaceutical grade, with magnesium oxide content ≥6.5%.

[0041] III. Detailed Implementation Method of Preparation 3.1 Raw material pretreatment Mulberry leaves, dried tangerine peel, poria cocos, kudzu root, bitter melon, and yam were separately ground in a universal grinder and passed through an 80-mesh sieve to obtain fine powders of each ingredient. Inulin, white kidney bean extract, L-arabinose, konjac flour, sea cucumber peptides, resistant starch, microcrystalline cellulose, calcium hydrogen phosphate, and magnesium stearate were also passed through an 80-mesh sieve for later use.

[0042] Input: Crude raw materials. Output: Fine powder of raw materials passing through an 80-mesh sieve. Key control points: Control the grinding temperature during the grinding process to not exceed 45℃ to avoid high-temperature deactivation of active ingredients; ensure uniform particle size of the material after sieving to guarantee uniformity in subsequent mixing.

[0043] 3.2 Mixing and Granulation Weigh out the pretreated inulin, mulberry leaf powder, white kidney bean extract, L-arabinose, konjac powder, tangerine peel powder, poria cocos powder, kudzu root powder, bitter melon powder, yam powder, sea cucumber peptide, resistant starch, microcrystalline cellulose, and dicalcium phosphate (except magnesium stearate) according to the weight ratio, place them in a three-dimensional motion mixer, and mix at a speed of 20-40 r / min for 20-40 minutes to obtain a mixture.

[0044] Add a 60%–80% (v / v) ethanol aqueous solution to the mixture as a wetting agent. The amount of wetting agent added is 15%–30% of the mass of the mixture. Stir to form a soft mass. The criteria for judging a soft mass are: it can be formed into a ball by hand, but it can be easily dispersed by light pressure. Place the soft mass in a vibrating granulator and granulate it through a 20-mesh sieve.

[0045] Input: Weighed raw material powders (except magnesium stearate). Output: Wet granules (particle size ≤ 20 mesh). Key control points: Mixing time should not be too long to avoid heat generation due to friction; too low an ethanol concentration can easily lead to material sticking, while too high a concentration will make granulation difficult; the moisture content of the soft material should be controlled between 25% and 35%.

[0046] 3.3 Drying The wet granules obtained in step 3.2 are evenly spread in a stainless steel tray with a layer thickness of 1-3 cm. The tray is then placed in a hot air circulating oven and dried at 45-55°C for 4-8 hours until the moisture content of the granules is 4%-6%. During the drying process, the granules are turned over every 1-2 hours to ensure uniform drying.

[0047] Input: Wet granules. Output: Dry granules (moisture content 4%–6%). Key control points: Drying temperature should not exceed 60℃ to avoid inactivation of heat-sensitive components such as α-amylase inhibitors in white kidney bean extract and DNJ in mulberry leaves; too low a moisture content (<3%) can easily lead to tablet cracking during compression, while too high a moisture content (>8%) can easily lead to sticking and insufficient tablet hardness.

[0048] 3.4 Granulation and Total Blending The dried granules are placed in a granulator and sieved through a 20-mesh sieve to ensure uniform particle size. Then, the weighed magnesium stearate is added and the mixture is placed in a V-type mixer and mixed at 10–20 rpm for 10–20 minutes to obtain granules for tableting. The angle of repose of the granules should be measured and should be ≤40° to ensure good flowability.

[0049] Input: Dry granules, magnesium stearate. Output: Granules for tableting. Key control points: The mixing time for magnesium stearate should not be too long (not exceeding 20 minutes), as over-mixing will reduce the disintegration properties of the granules; the mixed granules should have good flowability and compressibility.

[0050] 3.5 tablets Place the tableting granules in a rotary tablet press, adjust the tableting pressure to 10–25 kN, and compress into tablets with a weight of 0.5–1.0 g / tablet and a hardness of 40–120 N. Maintain the relative humidity of the tableting environment at 45%–60% and the temperature at 20–25℃.

[0051] Input: Granules for tableting. Output: Finished tableted candy. Key control points: Insufficient tableting pressure leads to insufficient tablet hardness and brittleness; excessive pressure may prolong disintegration time; excessively high ambient humidity can easily cause sticking and brittleness.

[0052] 3.6 Packaging and Storage The compressed tablets undergo quality inspection. Once qualified, they are packaged in aluminum-plastic blister packs or light-proof bottles and stored in a cool, dry place at a temperature ≤25℃ and a relative humidity ≤60%.

[0053] IV. Finished Product Quality Control The quality control standards for the compressed candies of this invention are as follows:

[0054] V. Examples Example 1

[0055] Recipe (total weight 1000g): Ingredients: 100g inulin, 80g mulberry leaves, 200g white kidney bean extract, 100g L-arabinose, 80g konjac powder, 50g dried tangerine peel, 80g poria cocos, 80g kudzu root, 80g bitter melon, 80g yam, 50g sea cucumber peptide, 100g resistant starch, 80g microcrystalline cellulose, 20g dicalcium phosphate, 20g magnesium stearate.

[0056] Preparation method: (1) Mulberry leaves, dried tangerine peel, poria cocos, kudzu root, bitter melon and yam are pulverized and passed through an 80-mesh sieve; inulin, white kidney bean extract, L-arabinose, konjac powder, sea cucumber peptide, resistant starch, microcrystalline cellulose, calcium hydrogen phosphate and magnesium stearate are passed through an 80-mesh sieve and set aside.

[0057] (2) Weigh all raw materials except magnesium stearate according to the formula, place them in a three-dimensional motion mixer, and mix at 30 r / min for 30 minutes to obtain a mixture. Add 70% ethanol aqueous solution (20% of the mass of the mixture) to the mixture, stir to form a soft material, and granulate through a 20-mesh sieve.

[0058] (3) Place the wet granules in a hot air circulating oven and dry them at 50°C for 6 hours until the moisture content of the granules is 5%.

[0059] (4) Strain the dry granules through a 20-mesh sieve, add magnesium stearate, and mix in a V-type mixer at 15 r / min for 15 minutes.

[0060] (5) Place the mixed granules in a rotary tablet press and press them into tablets at a pressure of 18 kN and an ambient humidity of 55%. The tablet weight is 0.6 g / tablet and the hardness is 60 N.

[0061] Example 2

[0062] Recipe (total weight 1000g): Ingredients: 150g inulin, 50g mulberry leaf, 250g white kidney bean extract, 80g L-arabinose, 50g konjac powder, 30g dried tangerine peel, 50g poria cocos, 50g kudzu root, 50g bitter melon, 50g yam, 30g sea cucumber peptide, 80g resistant starch, 50g microcrystalline cellulose, 10g dicalcium phosphate, 20g magnesium stearate.

[0063] Preparation method: (1) Same as step (1) in Example 1.

[0064] (2) Weigh all raw materials except magnesium stearate according to the formula, place them in a three-dimensional motion mixer, and mix at 25 r / min for 40 minutes to obtain a mixture. Add 65% ethanol aqueous solution (18% of the mass of the mixture) to the mixture, stir to form a soft material, and granulate through a 20-mesh sieve.

[0065] (3) Place the wet granules in a hot air circulating oven and dry them at 48°C for 7 hours until the moisture content of the granules is 4.5%.

[0066] (4) Same as step (4) in Example 1.

[0067] (5) Place the mixed granules in a rotary tablet press and press them into tablets at a pressure of 15 kN and an ambient humidity of 50%. The tablet weight is 0.8 g / tablet and the hardness is 55 N.

[0068] Example 3

[0069] Recipe (total weight 1000g): Ingredients: 80g inulin, 100g mulberry leaves, 150g white kidney bean extract, 150g L-arabinose, 100g konjac powder, 80g dried tangerine peel, 100g poria cocos, 100g kudzu root, 100g bitter melon, 100g yam, 80g sea cucumber peptide, 150g resistant starch, 150g microcrystalline cellulose, 30g dicalcium phosphate, 30g magnesium stearate.

[0070] Preparation method: (1) Same as step (1) in Example 1.

[0071] (2) Weigh all raw materials except magnesium stearate according to the formula, place them in a three-dimensional motion mixer, and mix at 35 r / min for 25 minutes to obtain a mixture. Add 75% ethanol aqueous solution (25% of the mass of the mixture) to the mixture, stir to form a soft material, and granulate through a 20-mesh sieve.

[0072] (3) Place the wet granules in a hot air circulating oven and dry them at 52°C for 5 hours until the moisture content of the granules is 5.5%.

[0073] (4) Same as step (4) in Example 1.

[0074] (5) Place the mixed granules in a rotary tablet press and press them into tablets at a pressure of 22kN and an ambient humidity of 58%. The tablet weight is 0.5g / tablet and the hardness is 80N.

[0075] VI. Experimental Examples Experimental Example 1: In vitro α-amylase inhibitory activity assay 1. Experimental Materials Samples: The compressed candy prepared in Example 1 was ground into a fine powder and prepared into test solutions of a series of concentrations (0.5, 1.0, 2.0, 4.0, 8.0 mg / mL) using phosphate buffered saline (PBS, pH 6.9).

[0076] Positive control: Acarbose (Glucobay), prepared in PBS to a series of concentrations.

[0077] Enzyme source: porcine pancreatic α-amylase (Sigma-Aldrich, activity ≥10 U / mg), prepared as a 1 U / mL enzyme solution with PBS.

[0078] Substrate: soluble starch, prepared as a 1% (w / v) solution in PBS.

[0079] Colorimetric reagent: 3,5-dinitrosalicylic acid (DNS) reagent.

[0080] 2. Experimental Methods The method described in the references was used to determine the α-amylase inhibitory activity using the DNS colorimetric method.

[0081] Add 200 μL of test solution (the control group was treated with an equal volume of PBS) and 200 μL of enzyme solution to a test tube, and incubate at 37°C for 10 minutes. Add 200 μL of starch substrate solution and react at 37°C for 15 minutes. Add 400 μL of DNS reagent and heat in a boiling water bath for 5 minutes to terminate the reaction. After cooling, measure the absorbance at 540 nm.

[0082] Inhibition rate calculation formula: Inhibition rate (%) = [1 - (Sample A - Sample A blank) / (Control A - Control A blank)] × 100% Wherein, Sample A is the absorbance after the reaction of the test solution, enzyme and substrate; Sample A blank is the absorbance of the test solution and substrate (without enzyme); Control A is the absorbance after the reaction of PBS, enzyme and substrate; Control A blank is the absorbance of PBS and substrate (without enzyme).

[0083] 3. Experimental Results

[0084] The positive control acarbose at a concentration of 1.0 mg / mL showed an α-amylase inhibition rate of 85.2 ± 3.1%.

[0085] 4. Conclusion The compressed candy of this invention exhibits significant inhibitory activity against α-amylase, and the inhibition rate is concentration-dependent. At a concentration of 4.0 mg / mL, the inhibition rate reached 68.9%, indicating that the α-amylase inhibitor in white kidney bean extract maintained good activity during the formulation process.

[0086] Experimental Example 2: In vitro α-glucosidase inhibitory activity assay 1. Experimental Materials Sample: Same as Experimental Example 1.

[0087] Positive control: Acarbose.

[0088] Enzyme source: α-glucosidase (derived from Saccharomyces cerevisiae, Sigma-Aldrich), prepared as an enzyme solution of 0.2 U / mL with PBS (pH 6.8).

[0089] Substrate: 4-nitrophenyl-α-D-glucopyranoside (pNPG), prepared as a 2.5 mmol / L solution in PBS.

[0090] 2. Experimental Methods Add 50 μL of test solution (or an equal volume of PBS for the control group) and 50 μL of enzyme solution sequentially to a 96-well plate, and incubate at 37°C for 10 minutes. Add 50 μL of pNPG substrate solution and react at 37°C for 20 minutes. Stop the reaction by adding 100 μL of Na₂CO₃ solution (0.2 mol / L), and measure the absorbance at 405 nm.

[0091] The formula for calculating the inhibition rate is the same as in Experiment Example 1.

[0092] 3. Experimental Results

[0093] The positive control acarbose at a concentration of 1.0 mg / mL showed an α-glucosidase inhibition rate of 89.6 ± 2.8%.

[0094] 4. Conclusion The compressed candy of this invention exhibits significant inhibitory activity against α-glucosidase, with an inhibition rate of 72.3% at a concentration of 4.0 mg / mL, which is close to the level of the positive control acarbose. This indicates that DNJ and other active ingredients in mulberry leaves maintain good α-glucosidase inhibitory activity during the formulation process.

[0095] Experimental Example 3: DPP-IV Inhibitory Activity Assay 1. Experimental Materials Samples: The compressed candy prepared in Example 1 was ground into a fine powder and prepared into test solutions of a series of concentrations (0.5, 1.0, 2.0, 4.0, 8.0 mg / mL) using Tris-HCl buffer (pH 8.0).

[0096] Positive control: Sitagliptin (DPP-IV inhibitor).

[0097] Enzyme source: Recombinant human DPP-IV (Sigma-Aldrich), prepared into appropriate activity units with Tris-HCl buffer.

[0098] Substrate: Gly-Pro-pNA (glycyl-prolyl-p-nitroaniline), prepared as a 0.2 mmol / L solution with Tris-HCl buffer.

[0099] 2. Experimental Methods Following the method described in the reference, 25 μL of test solution (with an equal volume of buffer added to the control group) and 50 μL of enzyme solution were added sequentially to a 96-well plate, and incubated at 37°C for 10 minutes. Then, 25 μL of substrate solution was added, and the reaction was carried out at 37°C for 30 minutes. The absorbance was measured at 405 nm.

[0100] The formula for calculating the inhibition rate is the same as in Experiment Example 1.

[0101] 3. Experimental Results

[0102] The positive control sitagliptin showed a DPP-IV inhibition rate of 92.5 ± 2.1% at a concentration of 1.0 μmol / L.

[0103] 4. Conclusion The compressed candy of this invention has significant inhibitory activity against DPP-IV, with an inhibition rate of 62.1% at a concentration of 4.0 mg / mL. This confirms that the DPP-IV inhibitory peptide in sea cucumber peptides maintains its activity during formulation and storage, and can exert an auxiliary hypoglycemic effect by reducing GLP-1 degradation.

[0104] VII. Comparative Experiment Comparative Experiment 1: Effects of Different Formulations on α-Amylase Inhibitory Activity 1. Experimental Design To verify the synergistic effect of the core components in the formulation of this invention, the following experimental groups were set up: Group A (Example 1 of the present invention): Full formula (containing all 15 kinds of raw materials such as white kidney bean extract, L-arabinose, mulberry leaves, etc.).

[0105] Group B (lacking white kidney bean extract): The white kidney bean extract is removed from the formulation of Example 1, and the rest remains unchanged.

[0106] Group C (L-arabinose missing): Based on the formulation of Example 1, L-arabinose is removed, and the rest remains unchanged.

[0107] Group D (Missing Mulberry Leaves): Based on the formula of Example 1, mulberry leaves are removed, and the rest remains unchanged.

[0108] Group E (lacking white kidney bean extract + L-arabinose + mulberry leaf): Based on the formulation of Example 1, remove three core enzyme inhibitor ingredients, and keep the rest unchanged.

[0109] Group F (White Kidney Bean Extract + L-Arabinose + Mulberry Leaf Combination Only): Composed of only 200g of white kidney bean extract, 100g of L-arabinose, and 80g of mulberry leaves (excluding other excipients and food-grade ingredients).

[0110] All samples were prepared into compressed candies according to the preparation method of Example 1 (Group F could not be compressed into tablets due to the lack of excipients and was tested as a powder mixture). The α-amylase inhibition rate of each sample at a concentration of 4.0 mg / mL was determined according to the method of Example 1.

[0111] 2. Experimental Results

[0112] 3. Analysis and Conclusion (1) The inhibition rate decreased most significantly after removing the white kidney bean extract (a decrease of 58.5%), indicating that the α-amylase inhibitor in the white kidney bean extract is the main contributor to the enzyme's inhibitory activity, which is consistent with the theory that the white kidney bean α-amylase inhibitor directly acts on starch digestive enzymes.

[0113] (2) The inhibition rate also decreased significantly after removing L-arabinose or mulberry leaf (by 24.1% and 19.0% respectively), but the decrease was less than that after removing white kidney bean extract. This is because L-arabinose mainly inhibits sucrase rather than α-amylase, and mulberry leaf DNJ mainly inhibits α-glucosidase rather than α-amylase. The three act on different links in the carbohydrate digestion chain and have a complementary relationship.

[0114] (3) The inhibition rate of group E (with all three enzyme inhibitors removed) dropped to 18.2%, leaving only basic activity (possibly from the non-specific effects of other components such as kudzu root and bitter melon), further confirming the indispensability of the three core enzyme inhibitor raw materials.

[0115] (4) The inhibition rate of group F (only three core ingredients) (61.4%) was lower than that of group A (68.9%), indicating that other food and medicine ingredients (such as kudzu root, bitter melon, yam, etc.) also have a certain synergistic enhancing effect on the inhibitory activity of α-amylase.

[0116] (5) The above results show that there is a significant synergistic effect among the components in the formulation of the present invention, rather than a simple additive effect.

[0117] Comparative Experiment 2: Effects of Different Preparation Processes on Tablet Quality and Retention of Active Ingredients 1. Experimental Design To determine the optimal preparation process parameters, the effect of drying temperature on tablet quality and retention of active ingredients was investigated based on the formulation of Example 1: Process A (this invention): Drying temperature 50℃, drying time 6 hours.

[0118] Process B (high temperature drying): Drying temperature 80℃, drying time 3 hours.

[0119] Process C (low temperature drying): Drying temperature 35℃, drying time 12 hours.

[0120] All other process parameters for each group are the same as in Example 1.

[0121] 2. Detection Indicators and Methods (1) Moisture content: direct drying method.

[0122] (2) Hardness: Tablet hardness tester.

[0123] (3) Disintegration time limit: Disintegration time limit tester.

[0124] (4) α-Amylase inhibitory activity retention rate: The α-amylase inhibition rate (4.0 mg / mL) of each process sample was determined according to the method in Experiment Example 1. The retention rate was calculated with the inhibition rate of the raw material mixture (an equal proportion of powder mixture without heat treatment) being 100%.

[0125] (5) DNJ retention rate: The DNJ content in mulberry leaves was determined by high performance liquid chromatography-evaporative light scattering detection (HPLC-ELSD). The retention rate was calculated with the DNJ content of the raw material mixture as 100%.

[0126] 3. Experimental Results

[0127] 4. Analysis and Conclusion (1) Process B (high temperature drying) Although the drying time is short and the efficiency is high, the retention rate of α-amylase inhibitory activity (58.3%) and DNJ retention rate (52.7%) are significantly lower than those of process A and process C, indicating that the α-amylase inhibitor in white kidney bean extract and DNJ in mulberry leaf are sensitive to high temperature. Drying above 80℃ will lead to significant degradation of active ingredients.

[0128] (2) Process C (low temperature drying) The retention rate of active ingredients is comparable to that of process A, but the drying time is too long (12 hours), resulting in low production efficiency and a high final moisture content (7.5%), which may lead to microbial growth and decreased tablet stability during storage.

[0129] (3) Process A (the present invention, 50℃ / 6h) achieves the best balance between the retention rate of active ingredients (α-amylase inhibitory activity 87.6%, DNJ 85.2%), tablet quality (hardness 61.2N, disintegration time 8.5min) and production efficiency.

[0130] (4) The above results show that the drying temperature of 45-55℃ selected in this invention is the best process window that balances the retention of active ingredients and tablet quality. Too high or too low a drying temperature is not conducive to the overall quality of the product.

[0131] Comparative Experiment 3: Blood Glucose Lowering Effect Test in Animals 1. Laboratory animals and modeling Fifty male SPF-grade SD rats, weighing 180–220 g, were selected. After one week of acclimatization, 10 rats were randomly selected as the normal control group (NC group), and the remaining 40 rats were fed a high-fat, high-sugar diet for four weeks. A type 2 diabetes model was then established by intraperitoneal injection of streptozotocin (STZ, 30 mg / kg). Fasting blood glucose was measured one week later; a blood glucose level ≥11.1 mmol / L was considered a successful model. The successfully modeled rats were randomly divided into four groups of ten each. Model control group (MC group): administered an equal volume of physiological saline by gavage.

[0132] This invention group (Example 1): Gavage administration of physiological saline suspension of the compressed candy of Example 1, at a dose of 500 mg / kg body weight (based on the dry weight of the candy).

[0133] Positive control group (PC group): Acarbose was administered by gavage at a dose of 20 mg / kg body weight.

[0134] Basic formulation group (BF group): The control formulation (without white kidney bean extract, L-arabinose and mulberry leaf) was administered by gavage at a dose of 500 mg / kg body weight.

[0135] 2. Drug administration and detection Each group was administered the drug once daily by gavage for 28 consecutive days. Fasting blood glucose (FBG) was measured before administration (day 0) and on days 7, 14, 21, and 28 after administration. Following the last administration on day 28, an oral glucose tolerance test (OGTT) was performed: rats in each group were administered glucose (2.0 g / kg) by gavage, and blood glucose was measured via tail vein at 0, 30, 60, and 120 minutes. The area under the blood glucose curve (AUC) was calculated.

[0136] 3. Experimental Results Table 1. Changes in fasting blood glucose in rats of each group (mmol / L, mean±SD, n=10)

[0137] Note: Compared with the MC group, *p<0.05, **p<0.01.

[0138] Table 2. AUC of blood glucose in rats during OGTT (mmol·h / L, mean±SD, n=10)

[0139] Note: Compared with the MC group, **p<0.01.

[0140] 4. Analysis and Conclusion (1) After 28 days of administration, the fasting blood glucose of rats in the present invention group decreased from 15.6 mmol / L to 8.6 mmol / L, a decrease of 44.9%, which was comparable to the positive control acarbose group (decreased from 15.7 mmol / L to 8.1 mmol / L, a decrease of 48.4%). There was no statistically significant difference between the two (p>0.05).

[0141] (2) After 28 days of administration, the fasting blood glucose of the basic formula group (BF group, without the three core enzyme inhibitors) only decreased from 15.9 mmol / L to 14.5 mmol / L, a decrease of only 8.8%, which was not significantly different from the model control group (p>0.05). This indicates that the hypoglycemic effect of the formula was basically lost after removing white kidney bean extract, L-arabinose and mulberry leaf.

[0142] (3) The OGTT results showed that the blood glucose AUC (22.3 mmol·h / L) of the present invention group was 42.2% lower than that of the model control group (38.6 mmol·h / L), indicating that the compressed candy of the present invention can significantly improve glucose tolerance in diabetic rats.

[0143] (4) The above results confirm that the compressed candy of the present invention has a significant hypoglycemic effect in animals. Its mechanism of action mainly depends on the synergistic inhibition of carbohydrate digestive enzymes by white kidney bean extract, L-arabinose and mulberry leaf. At the same time, the DPP-IV inhibition of sea cucumber peptide and the sustained release effect of dietary fiber are also involved.

[0144] Based on the combined results of in vitro enzyme inhibition experiments, process comparison experiments, and in vivo hypoglycemic experiments in animals, this invention has the following significant effects: First, the compressed candy of the present invention exhibits significant inhibitory activity against α-amylase, α-glucosidase and DPP-IV in vitro, and the three work synergistically to form a multi-target hypoglycemic mechanism.

[0145] Second, there is a significant synergistic effect among the components in the formula. In particular, the three core enzyme inhibitor raw materials, namely white kidney bean extract, L-arabinose and mulberry leaf, are indispensable. Removing any one of them will lead to a significant decrease in the blood sugar lowering effect.

[0146] Third, the preparation process determined in this invention (drying temperature 45-55℃, water content 4%-6%) ensures good tablet quality (hardness 40-120N, disintegration time ≤15min) while maximizing the retention of heat-sensitive active ingredients (α-amylase inhibitor retention rate >85%, DNJ retention rate >85%).

[0147] Fourth, in vivo animal experiments have confirmed that the compressed candy of the present invention, when administered continuously for 28 days, can reduce fasting blood glucose by 44.9% and significantly improve glucose tolerance (AUC decreased by 42.2%) in diabetic model rats, with effects comparable to the positive control acarbose.

[0148] Fifth, the raw materials used in this invention are all medicinal and edible materials or food-grade excipients, which are highly safe, suitable for long-term use, and have good market development prospects.

[0149] Dosage Form Expansion and Application Prospects The food-medicine homology raw material composition described in this invention is not only suitable for compressed candies, but can also be further developed into various oral dosage forms such as oral liquids, powders, granules, or capsules based on conventional pharmaceutical techniques. Specific directions for expansion are as follows: (1) Oral liquid: Take the water-soluble raw materials (inulin, L-arabinose, white kidney bean extract, sea cucumber peptide, resistant starch, etc.) in the formula of this invention and the water-concentrated extracts of mulberry leaves, tangerine peel, poria cocos, kudzu root, bitter melon, yam and other medicinal and edible raw materials, add purified water and appropriate suspending agents (such as xanthan gum) and preservatives (such as potassium sorbate), adjust the pH to 4.5-6.5, homogenize, filter, fill and sterilize (pasteurization or ultra-high temperature instantaneous sterilization can be used to protect heat-sensitive components) to obtain the oral liquid. This dosage form is absorbed quickly and is convenient to take, especially suitable for the elderly and people with difficulty swallowing.

[0150] (2) Powder: The fine powders of each raw material are directly mixed evenly according to the formula ratio, sieved and packaged. This dosage form has the fewest processing steps, is most beneficial for the protection of heat-sensitive active ingredients, and is easy to adjust the dosage according to individual needs. It can also be made into granules (after wet or dry granulation and packaging) to improve the flowability and moisture resistance of the powder.

[0151] (3) Capsules: The above-mentioned mixed powder or dry granulated granules are filled into hard capsule shells to make capsules, which can mask unpleasant odors and improve compliance.

[0152] The preparation of each of the above dosage forms can refer to the raw material pretreatment and mixing process of the embodiments of the present invention, with only adaptive adjustments made to the molding steps. The composition of the core active ingredients and the synergistic hypoglycemic mechanism remain unchanged, and all are reasonable modifications to the technical solution of the present invention. The present invention provides ample technical reserves and process references for the subsequent development of multi-dosage form, serialized auxiliary hypoglycemic functional foods.

[0153] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A compressed candy containing a medicinal and edible ingredient with hypoglycemic effect, characterized in that, It is prepared from the following raw materials in parts by weight: Inulin 5-20 parts, mulberry leaf 3-15 parts, white kidney bean extract 10-30 parts, L-arabinose 5-20 parts, konjac powder 3-15 parts, dried tangerine peel 2-10 parts, poria cocos 3-12 parts, kudzu root 3-12 parts, bitter melon 3-12 parts, yam 3-12 parts, sea cucumber peptide 1-10 parts, resistant starch 5-20 parts, microcrystalline cellulose 5-20 parts, dicalcium phosphate 0.5-5 parts, magnesium stearate 0.5-3 parts.

2. The compressed candy containing a medicinal and edible ingredient with hypoglycemic effect according to claim 1, characterized in that, It is prepared from the following raw materials in parts by weight: Inulin 8-15 parts, mulberry leaf 5-10 parts, white kidney bean extract 15-25 parts, L-arabinose 8-15 parts, konjac powder 5-10 parts, dried tangerine peel 3-8 parts, poria cocos 5-10 parts, kudzu root 5-10 parts, bitter melon 5-10 parts, yam 5-10 parts, sea cucumber peptide 3-8 parts, resistant starch 8-15 parts, microcrystalline cellulose 8-15 parts, dicalcium phosphate 1-3 parts, magnesium stearate 1-2 parts.

3. The compressed candy containing a medicinal and edible ingredient with hypoglycemic effect according to claim 1, characterized in that, The white kidney bean extract contains an α-amylase inhibitor, the L-arabinose selectively inhibits the activity of sucrase in the small intestinal mucosa, and the mulberry leaf contains 1-deoxynojirimycin; The three work together to inhibit the process of carbohydrate hydrolysis into monosaccharides, blocking or delaying the production and absorption of glucose.

4. The compressed candy containing a medicinal and edible ingredient with hypoglycemic effect according to claim 1, characterized in that, The sea cucumber peptide has the effect of inhibiting dipeptidyl peptidase-IV activity, and the resistant starch is a complex carbohydrate that is not broken down by small intestinal enzymes; the two work synergistically to delay glucose release and increase insulin levels in the body.

5. The compressed candy containing a medicinal and edible ingredient with hypoglycemic effect according to claim 1, characterized in that, The microcrystalline cellulose and dicalcium phosphate are used as fillers, and the magnesium stearate is used as a lubricant. The three together are used to improve tableting properties and tablet demolding performance.

6. A method for preparing a compressed candy containing a food-medicine homologous ingredient with hypoglycemic effect as described in any one of claims 1 to 5, characterized in that, Includes the following steps: (1) Raw material pretreatment: Mulberry leaves, dried tangerine peel, Poria cocos, kudzu root, bitter melon and yam are pulverized and passed through a 60-120 mesh sieve to obtain fine powder of each raw material; Inulin, white kidney bean extract, L-arabinose, konjac powder, sea cucumber peptide, resistant starch, microcrystalline cellulose, dicalcium phosphate and magnesium stearate are passed through a 60-120 mesh sieve for later use; (2) Mixing and granulation: Weigh all the raw materials except magnesium stearate after step (1) according to the weight parts, put them in a mixer and mix them evenly to obtain a mixture; add an ethanol aqueous solution as a wetting agent to the mixture, stir to make a soft material, and granulate it through a 10-30 mesh sieve. (3) Drying: Place the wet granules obtained in step (2) in a drying device and dry them until the moisture content of the granules is 3% to 8% to obtain dry granules; (4) Granulation and mixing: The dry granules obtained in step (3) are granulated by passing them through a 10-30 mesh sieve, and then magnesium stearate is added and mixed evenly to obtain granules for tableting. (5) Tableting: Place the tableting granules obtained in step (4) into a tablet press and compress them into tablets to obtain tablets containing food and medicine homologous ingredients with hypoglycemic effect.

7. The preparation method according to claim 6, characterized in that, The volume concentration of the ethanol aqueous solution in step (2) is 50% to 95%, and the mixing time is 10 to 60 minutes.

8. The preparation method according to claim 6, characterized in that, The drying equipment mentioned in step (3) is an oven or fluidized bed drying equipment, with a drying temperature of 40-60℃ and a moisture content of 4%-6% for the dried particles.

9. The preparation method according to claim 6, characterized in that, The tableting pressure in step (5) is 5 to 30 kN, and the hardness of the resulting tablet is 30 to 150 N.

10. The use of the compressed candy containing a food-derived ingredient with hypoglycemic effect according to any one of claims 1 to 5 in the preparation of auxiliary hypoglycemic foods or health foods.